Metastatic renal cell carcinoma treated with Peg-interferon alfa-2b

References

• Collaborators MRCRC. Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999;353:14–7.
   PubMedGoogle Scholar
• Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 1985; 3: 1522–8
   PubMed Web of Science ®Google Scholar
• Figlin RA, deKernion JB, Mukamel E, Palleroni AV, Itri LM, Sarna GP. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: Assessment of antitumor activity and anti-interferon antibody formation. J Clin Oncol 1988; 6: 1604–10
   PubMed Web of Science ®Google Scholar
• Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993; 20: 283–95
   PubMed Web of Science ®Google Scholar
• Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 2859–67
   PubMed Web of Science ®Google Scholar
• Bracarda, S ECea. Sorafenib plus interferon alpha-2b in metastatic renal cell carcinoma: Results from RAPSODY (GOIRC Study 0681)-A randomized prospective Phase II Trial of two different treatment schedules. EAU 2008-23rd Annual EAU Congress. 2008.
   Google Scholar
• Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007; 370: 2103–11
   PubMed Web of Science ®Google Scholar
• Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556–67
   PubMed Web of Science ®Google Scholar
• Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002; 54: 547–70
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rakhit A, Thompson J, Gurney H, Selby P, Figlin R, et al. Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol 2002; 13: 1799–805
   PubMed Web of Science ®Google Scholar
• Chang E, Boyd A, Nelson CC, Crowley D, Law T, Keough KM, et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol 1997; 19: 237–44
   PubMed Web of Science ®Google Scholar
• Berg WJ, Divgi CR, Nanus DM, Motzer RJ. Novel investigative approaches for advanced renal cell carcinoma. Semin Oncol 2000; 27: 234–9
   PubMed Web of Science ®Google Scholar
• Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000; 163: 343–7
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, et al. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 2001; 19: 1312–9
   PubMed Web of Science ®Google Scholar
• Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: A randomised study. Gut 2008; 57: 525–30
   PubMedGoogle Scholar
• Michallet M, Maloisel F, Delain M, Hellmann A, Rosas A, Silver RT, et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: A phase III study. Leukemia 2004; 18: 309–15
   PubMed Web of Science ®Google Scholar
• Bukowski R, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato R, Gupta SK, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: A phase I/II study. J Clin Oncol 2002; 20: 3841–9
   PubMed Web of Science ®Google Scholar
• Bex A, Mallo H, Kerst M, Haanen J, Horenblas S, de Gast GC. A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. Cancer Immunol Immunother 2005; 54: 713–9
   PubMedGoogle Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16
   PubMed Web of Science ®Google Scholar
• Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13: 346–53
   PubMedGoogle Scholar
• Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000; 32: 647–53
   PubMed Web of Science ®Google Scholar
• Melichar B, Koralewski P, Ravaud A, Pluzanska A, Bracarda S, Szczylik C, et al. First-line bevacizumab combined with reduced dose interferon-{alpha}2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008; 19: 1470–6
   PubMed Web of Science ®Google Scholar
• Fossa S, Jones M, Johnson P, Joffe J, Holdener E, Elson P, et al. Interferon-alpha and survival in renal cell cancer. Br J Urol 1995; 76: 286–90
   PubMedGoogle Scholar
• Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655–9
   PubMed Web of Science ®Google Scholar
• Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48: 7310–3
   PubMed Web of Science ®Google Scholar
• Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 1994; 30A: 1310–4
   PubMedGoogle Scholar
• Negrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002; 13: 1460–8
   PubMed Web of Science ®Google Scholar
• Alamdari FI, Rasmuson T, Grankvist K, Ljungberg B. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma. Scand J Urol Nephrol 2007; 41: 5–9
   PubMed Web of Science ®Google Scholar
• Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986; 4: 234–43
   PubMed Web of Science ®Google Scholar
• Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, et al. Single-dose pharmacokinetics and safety of pegylated interferon-α2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002; 42: 1109–15
   PubMed Web of Science ®Google Scholar